Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

KNSA Kiniksa Pharmaceuticals Ltd.

休市中 08-30 16:00:00 EDT

26.74

-0.02

-0.07%

盘后26.74

+0.000.00%

16:02 EDT

最高27.11	最低26.48	成交量22.73万
今开26.68	昨收26.76	日振幅2.35%
总市值19.05亿	流通市值3.87亿	总股本7,124万
成交额607.97万	换手率1.57%	流通股本1,448万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"KNSA","market":"US","secType":"STK","nameCN":"Kiniksa Pharmaceuticals Ltd.","latestPrice":26.74,"timestamp":1725048000000,"preClose":26.76,"halted":0,"volume":227263,"hourTrading":{"tag":"盘后","latestPrice":26.74,"preClose":26.74,"latestTime":"16:02 EDT","volume":11967,"amount":319997.58,"timestamp":1725048144482},"delay":0,"floatShares":14477605,"shares":71243712,"eps":-0.147781,"marketStatus":"休市中","marketStatusCode":7,"change":-0.02,"latestTime":"08-30 16:00:00 EDT","open":26.68,"high":27.11,"low":26.48,"amount":6079724.776642,"amplitude":0.023543,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.147781,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1725350400000},"adr":0,"listingDate":1527134400000,"adjPreClose":26.76,"adrRate":0,"postHourTrading":{"tag":"盘后","latestPrice":26.74,"preClose":26.74,"latestTime":"16:02 EDT","volume":11967,"amount":319997.58,"timestamp":1725048144482},"volumeRatio":0.8816817765561503,"impliedVol":0.3587,"impliedVolPercentile":0.127},"requestUrl":"/m/hq/s/KNSA","defaultTab":"news","newsList":[{"id":"2456328292","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.12%报24.45美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2456328292","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456328292?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:31","pubTimestamp":1722605515,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时31分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅下跌5.12%。截至发稿，该股报24.45美元/股，成交量1.5912万股，换手率0.02%，振幅1.98%。Kiniksa Pharmaceuticals, Ltd.股票所在的制药行业中，整体跌幅为0.91%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213156aefcf854&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213156aefcf854&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2454787268","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘快速拉升5.14%报26.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2454787268","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2454787268?lang=zh_cn&edition=full","pubTime":"2024-07-25 22:08","pubTimestamp":1721916518,"startTime":"0","endTime":"0","summary":"北京时间2024年07月25日22时08分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价大幅上涨5.14%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体涨幅为0.99%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725220839af941f88&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240725220839af941f88&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2453370740","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘大幅拉升9.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453370740","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453370740?lang=zh_cn&edition=full","pubTime":"2024-07-23 21:31","pubTimestamp":1721741478,"startTime":"0","endTime":"0","summary":"北京时间2024年07月23日21时31分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价急速拉升9.05%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体跌幅为0.12%。其相关个股中，Adial Pharmaceuticals, Inc、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Mesoblast Ltd涨幅较大，Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Aditxt, Inc.较为活跃，换手率分别为507.63%、58.79%、54.11%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Hcw Biologics Inc.、Monte Rosa Therapeutics, Inc.，振幅分别为26.42%、10.48%、8.17%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407232131189ee2b33a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407232131189ee2b33a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2453822033","title":"Kiniksa Pharmaceuticals(KNSA.US)：2024年Q2财报实现营收1.086亿美元，前值为7147.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453822033","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453822033?lang=zh_cn&edition=full","pubTime":"2024-07-23 19:34","pubTimestamp":1721734480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2452157444","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 快速下挫5.55%报21.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452157444","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452157444?lang=zh_cn&edition=full","pubTime":"2024-07-17 21:30","pubTimestamp":1721223051,"startTime":"0","endTime":"0","summary":"北京时间2024年07月17日21时30分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速下挫5.55%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Aditxt, Inc.、Aptevo Therapeutics Inc.、Longeveron Inc.涨幅较大，Aditxt, Inc.、Aptevo Therapeutics Inc.、Longeveron Inc.较为活跃，换手率分别为616.34%、454.78%、91.01%，振幅较大的相关个股有Aditxt, Inc.、Terns Pharmaceuticals, Inc.、Kazia Therapeutics Limited，振幅分别为6.88%、6.34%、4.37%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals International PLC是一家处于临床阶段的生物制药公司，致力于发现、收购、开发和商业化治疗衰弱性疾病患者的药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717213051aefa2517&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240717213051aefa2517&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":1},{"id":"2448491699","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大跌5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2448491699","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448491699?lang=zh_cn&edition=full","pubTime":"2024-07-01 21:46","pubTimestamp":1719841613,"startTime":"0","endTime":"0","summary":"北京时间2024年07月01日21时46分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价急速跳水5.36%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体涨幅为0.70%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701214654968186ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701214654968186ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2432518834","title":"Kiniksa Pharmaceuticals(KNSA.US)获富国银行首次覆盖，给予增持评级, 目标价34.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432518834","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432518834?lang=zh_cn&edition=full","pubTime":"2024-05-04 00:05","pubTimestamp":1714752314,"startTime":"0","endTime":"0","summary":"Kiniksa Pharmaceuticals(KNSA.US)获富国银行首次覆盖，给予增持评级, 目标价34.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040005198b70c8c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405040005198b70c8c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2432908679","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 大幅拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432908679","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432908679?lang=zh_cn&edition=full","pubTime":"2024-05-03 21:32","pubTimestamp":1714743124,"startTime":"0","endTime":"0","summary":"北京时间2024年05月03日21时32分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价大幅上涨5.21%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体跌幅为0.15%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。该信息摘要如下：小摩：维持Kiniksa Pharmaceuticals评级，由增持调整至增持评级, 目标价由26.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503213205861ead38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240503213205861ead38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VAXX","BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2432261638","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2432261638","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432261638?lang=zh_cn&edition=full","pubTime":"2024-05-02 02:42","pubTimestamp":1714588936,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日02时42分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价大幅上涨5.24%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体涨幅为1.75%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。该信息摘要如下：小摩：维持Kiniksa Pharmaceuticals评级，由增持调整至增持评级, 目标价由26.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502024216861ea927&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240502024216861ea927&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4139","BK4505"],"gpt_icon":0},{"id":"2432501614","title":"小摩：维持Kiniksa Pharmaceuticals(KNSA.US)评级，由增持调整至增持评级, 目标价由26.00美元调整至30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432501614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2432501614?lang=zh_cn&edition=full","pubTime":"2024-05-01 22:55","pubTimestamp":1714575342,"startTime":"0","endTime":"0","summary":"小摩：维持Kiniksa Pharmaceuticals(KNSA.US)评级，由增持调整至增持评级, 目标价由26.00美元调整至30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012255468b6a27f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012255468b6a27f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2430371437","title":"Kiniksa Pharmaceuticals, Ltd.2024财年第一财季实现净利润-17.70百万美元，同比减少44.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430371437","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2430371437?lang=zh_cn&edition=full","pubTime":"2024-04-27 06:09","pubTimestamp":1714169379,"startTime":"0","endTime":"0","summary":"3月31日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2024财年第一财季净利润为-17.70百万美元，同比减少44.25%；其中营业收入为79.86百万美元，同比增加65.17%，每股基本收益为-0.25美元。机构评级：截至2024年3月31日，当前有5家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为29.20美元，其中最低目标价为26.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270609488b589edf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404270609488b589edf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2429112842","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 快速上涨5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429112842","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2429112842?lang=zh_cn&edition=full","pubTime":"2024-04-24 00:03","pubTimestamp":1713888181,"startTime":"0","endTime":"0","summary":"北京时间2024年04月24日00时03分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速上涨5.06%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体涨幅为1.38%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240003017a54f36b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404240003017a54f36b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA","BK4505","BK4139"],"gpt_icon":0},{"id":"2429193791","title":"Kiniksa Pharmaceuticals(KNSA.US)：2024年Q1财报实现营收7985.8万美元，前值为4834.","url":"https://stock-news.laohu8.com/highlight/detail?id=2429193791","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2429193791?lang=zh_cn&edition=full","pubTime":"2024-04-23 19:33","pubTimestamp":1713871994,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","BK4139","KNSA"],"gpt_icon":0},{"id":"2424495220","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2424495220","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2424495220?lang=zh_cn&edition=full","pubTime":"2024-04-02 22:03","pubTimestamp":1712066637,"startTime":"0","endTime":"0","summary":"北京时间2024年04月02日22时03分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价急速下挫5.08%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体跌幅为1.59%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040222035787e7da40&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024040222035787e7da40&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2416286161","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 早盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416286161","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416286161?lang=zh_cn&edition=full","pubTime":"2024-03-04 23:28","pubTimestamp":1709566123,"startTime":"0","endTime":"0","summary":"北京时间2024年03月04日23时28分，Kiniksa Pharmaceuticals, Ltd.股票出现异动，股价快速跳水5.11%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体跌幅为0.06%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030423284387e75b34&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030423284387e75b34&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNSA","BK4505"],"gpt_icon":0},{"id":"2416906760","title":"Kiniksa Pharmaceuticals, Ltd.2023财年实现净利润14.08百万美元，同比减少92.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416906760","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416906760?lang=zh_cn&edition=full","pubTime":"2024-03-04 00:19","pubTimestamp":1709482772,"startTime":"0","endTime":"0","summary":"12月31日，Kiniksa Pharmaceuticals, Ltd.公布财报，公告显示公司2023财年净利润为14.08百万美元，同比减少92.31%；其中营业收入为2.70亿美元，同比增加22.73%，每股基本收益为0.20美元。机构评级：截至2023年12月31日，当前有5家机构对Kiniksa Pharmaceuticals, Ltd.目标价做出预测，其中目标均价为27.40美元，其中最低目标价为24.00美元，最高目标价为32.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400194087e0df1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030400194087e0df1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["KNSA"],"gpt_icon":0},{"id":"2416757125","title":"Kiniksa Pharmaceuticals, Ltd.盘中异动 股价大涨5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416757125","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2416757125?lang=zh_cn&edition=full","pubTime":"2024-03-01 01:55","pubTimestamp":1709229343,"startTime":"0","endTime":"0","summary":"北京时间2024年03月01日01时55分，Kiniksa Pharmaceuticals, Ltd.股票出现波动，股价快速拉升5.21%。Kiniksa Pharmaceuticals, Ltd.股票所在的生物技术行业中，整体跌幅为1.34%。Kiniksa Pharmaceuticals, Ltd.公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030101554487e74f1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030101554487e74f1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","KNSA","BK4505"],"gpt_icon":0},{"id":"2415209743","title":"Kiniksa Pharmaceuticals Ltd盘中异动 早盘股价大跌5.52%报19.74美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2415209743","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2415209743?lang=zh_cn&edition=full","pubTime":"2024-02-28 22:31","pubTimestamp":1709130692,"startTime":"0","endTime":"0","summary":"北京时间2024年02月28日22时31分，Kiniksa Pharmaceuticals Ltd股票出现异动，股价大幅下挫5.52%。截至发稿，该股报19.74美元/股，成交量4.3991万股，换手率0.06%，振幅10.77%。Kiniksa Pharmaceuticals Ltd股票所在的生物技术行业中，整体跌幅为0.23%。Kiniksa Pharmaceuticals Ltd公司简介：Kiniksa Pharmaceuticals Ltd 是一家临床阶段的生物制药公司，专注于为患有衰弱性疾病的患者发现、获取、开发和商业化治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022822313279158bd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022822313279158bd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0},{"id":"2414323248","title":"Kiniksa Pharmaceuticals(KNSA.US)：2023年Q4财报实现营收8339.5万美元，前值为6188.","url":"https://stock-news.laohu8.com/highlight/detail?id=2414323248","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2414323248?lang=zh_cn&edition=full","pubTime":"2024-02-28 20:44","pubTimestamp":1709124241,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4505","KNSA","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kiniksa.com","stockEarnings":[{"period":"1week","weight":-0.0234},{"period":"1month","weight":0.0053},{"period":"3month","weight":0.4066},{"period":"6month","weight":0.23},{"period":"1year","weight":0.5519},{"period":"ytd","weight":0.5245}],"compareEarnings":[{"period":"1week","weight":0.0028},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0689},{"period":"6month","weight":0.0991},{"period":"1year","weight":0.2516},{"period":"ytd","weight":0.1859}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Kiniksa Pharmaceuticals International, plc于2015年7月21日在百慕大成立。该公司于2024年6月28日将公司注册地由百慕大变更为英国。该公司是一家生物制药公司，专注于发现、获取、开发和商业化治疗药物，为患有严重未满足医疗需求的使人衰弱的疾病的患者提供治疗药物。该公司的免疫调节组合ARCALYST、KPL-404和mavrilimumab基于强大的生物学原理或经过验证的机制，针对一系列未得到充分治疗的心血管和自身免疫疾病，并提供差异化的潜力。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.001355},{"month":2,"riseRate":0.666667,"avgChangeRate":0.05427},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.08579},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.018132},{"month":5,"riseRate":0.666667,"avgChangeRate":0.00357},{"month":6,"riseRate":0.714286,"avgChangeRate":0.058257},{"month":7,"riseRate":0.571429,"avgChangeRate":0.047135},{"month":8,"riseRate":0.428571,"avgChangeRate":0.021715},{"month":9,"riseRate":0.5,"avgChangeRate":-0.000526},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.120523},{"month":11,"riseRate":1,"avgChangeRate":0.236104},{"month":12,"riseRate":0.666667,"avgChangeRate":0.060395}],"exchange":"NASDAQ","name":"Kiniksa Pharmaceuticals Ltd.","nameEN":"Kiniksa Pharmaceuticals Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kiniksa Pharmaceuticals Ltd.,KNSA,Kiniksa Pharmaceuticals Ltd.股票,Kiniksa Pharmaceuticals Ltd.股票老虎,Kiniksa Pharmaceuticals Ltd.股票老虎国际,Kiniksa Pharmaceuticals Ltd.行情,Kiniksa Pharmaceuticals Ltd.股票行情,Kiniksa Pharmaceuticals Ltd.股价,Kiniksa Pharmaceuticals Ltd.股市,Kiniksa Pharmaceuticals Ltd.股票价格,Kiniksa Pharmaceuticals Ltd.股票交易,Kiniksa Pharmaceuticals Ltd.股票购买,Kiniksa Pharmaceuticals Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kiniksa Pharmaceuticals Ltd.(KNSA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kiniksa Pharmaceuticals Ltd.(KNSA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}